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Abstract
Background:  Systemic lupus erythematosus (SLE) is a representative systemic autoimmune
disease characterized by activated T cells and polyclonally activated B cells that produce
autoantibodies. Activation of autoreactive T and B cells plays a pivotal role in the pathogenesis of
this disease. A role of focal adhesion kinase (FAK) in the pathogenesis has been suggested. Proline-
rich tyrosine kinase2 (PYK2) is structurally related to FAK, however, the functional activation of
PYK2 in SLE remains unclear. In the present study, we showed that PYK2 is significantly increased
and activated in peripheral blood mononuclear cells (PBMCs) of patients with SLE. In addition, we
showed the involvement of PYK2 proteins in the up-regulation of CD40L and CTLA4 expression
and PBMC proliferation.
Methods: Freshly isolated PBMCs from 48 SLE patients, 32 patients with rheumatoid arthritis(RA)
and 24 healthy individuals were analyzed for the expression and activation of PYK2 by western-
blotting and immunocytochemistry. The other isolated PBMCs from patients with this condition
were cultured and stimulated with PMA or TyrA9, and then the expression of costimulatory
molecules CD40L and CTLA4 was evaluated using flow cytometry, PBMCs proliferation was
determined with [3H]-thymidine incorporation (CPM).
Results: Compared with RA patients and healthy donors, PBMCs from SLE patients expressed
more of both the total PYK2 protein and its activated/phosphorylated form. The increase of
activated PYK2 protein in SLE PBMCs was correlated with the complication of nephritis and
inversly associated the level of serum complements. In active SLE patients, activation of PYK2 in
PBMCs is accompanying the increased cell proliferation and the induced expression of
costimulatory molecules CD40L and CTLA4.
Conclusion: Our findings indicate that phosphorylated PYK2 in SLE PBMCs may induce the
expression of CD40L and CTLA4, and subsequently the cell proliferation. PYK2 signaling enhances
the autoreactive lymphocyte activation and plays an important role in the pathogenesis of SLE.
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Background
Systemic lupus erythematosus (SLE) is a representative
systemic autoimmune disease characterized by activated T
cells and polyclonally activated B cells that produce
autoantibodies. Activation of autoreactive T and B cells
plays a pivotal role in the pathogenesis of this disease
[1,2]. Although SLE T cells have impaired interleukin-2
(IL-2) production and proliferative response to stimula-
tion of the T cell receptor-CD3 compound[3,4], expres-
sion of costimulatory molecules such as CD40L and
CTLA4, which is essential for lymphocyte activation [5,6],
is up-regulated [7-10]. These molecules are thus targets in
considering effective strategies in the treatment of SLE.
Lupus mice treated with antibody against CD40L or
CTLA4-Ig have lower level of anti-doublestranded DNA
antibodies, later development of nephritis, and prolonged
survival time [11-13]. In patients with SLE, the reduced
expression of CD28 costimulatory molecule on both
CD4- and CD8-T cells is also well documented [14,15].
CD28-mediated costimulatory activity, following the
interaction of T cells with B cells, is significantly decreased
in patients with SLE [14]. Thus, it seems that costimula-
tory signals in SLE T cells may differ from those present in
normal T cells.
Lately, in SLE T cells, focal adhesion kinase (FAK) have
been shown to be involved in costimulatory molecule
expression and cell proliferation[16]. Similar findings
regarding the involvement of FAK were also reported in
other inflammation-related diseases, such as rheumatoid
arthrithis (RA)[17,18], diabetes[19], chronic inflamma-
tory bowel diseases[20] and asthma[21]. It is thus likely
that FAK may represent a new molecular target for the
anti-inflammatory treatment.
The proline-rich tyrosine kinase 2 (PYK2) is a nonreceptor
protein tyrosine kinase that is structurally related to FAK
[22]. It is also known as cell adhesion kinase-β or related
adhesion focal tyrosine kinase. Unlike the ubiquitous
expression of prototype FAK, PYK2 is primarily expressed
in populations of neuronal and hematopoetic cells[23].
PYK2 becomes activated in response to stimulation
through a number of receptors, of which include
integrins[24,25], cytokine receptors [26-28] and lym-
phocyte antigen receptors [29-31]. Numerous studies over
the years have shown that PYK2 provides important sig-
nals during the activation of lymphocytes [32-35]. How-
ever, in SLE, PYK2's expression and activation in PBMCs,
as well as the functional significance of PYK2 in T cell and
B cell activation, remains unclear.
In this study, we showed that PYK2 is significantly
increased and activated in PBMCs of patients with active
SLE. In addition, we showed the involvement of PYK2
proteins in the up-regulation of CD40L and CTLA4
expression and PBMCs proliferation.
Methods
The study protocol was approved by the Human Ethics
Review Committee of Shandong Provincial Hospital,
Jinan, China. A signed consent form was obtained from
each subject prior to study participation.
Subjects
The study subjects were 24 healthy volunteers, 32 RA
patients (6 men and 26 women, mean age 42.3 years
[range 21-67 years]), and 48 SLE patients (7 men and 41
women, mean age 33.9 years [range 11-69 years]), of
whom 12 had inactive SLE disease and 36 had active SLE
disease at the time of the study. All patients fulfilled the
diagnostic criteria of the American College of Rheumatol-
ogy for the classification of SLE or RA [36,37]. All SLE
patients were admitted to our department between 2006
and 2009, and SLE disease activity was evaluated by the
SLE Disease Activity Index (SLEDAI) score[38]. Patients
were classified as having inactive disease if the SLEDAI
score was persistently ≤9 for at least 3 months prior to the
study. Patients with active disease had a SLEDAI score of
≥10 at the time of the study. Ten patients, 9 of whom had
newly diagnosed SLE, were receiving no treatment at the
time of the study. Thirty-eight SLE patients were receiving
low-dose steroids (≤10 mg/day prednisolone) and/or
immunosuppressive agents (cyclophosphamide). None
of the SLE patients were receiving prednisolone at a dos-
age of ≥10 mg/day. Twenty-nine patients had biopsy-
proven proliferative lupus nephritis (World Health
Organization [WHO] class IV [39]), 8 had WHO class II
nephritis, 4 had WHO class V nephritis, 7 had WHO class
I nephritis, and 6 had central nervous system (CNS) man-
ifestations. The clinical features of patients with and with-
out active SLE are summarized in Table 1. All enrolled
patients with RA had >6 swollen joints, >6 tender joints,
and an erythrocyte sedimentation rate (Westergren) of
>30 mm/hour. Twenty-six RA patients were receiving low-
dose steroids (≤10 mg/day prednisolone) and/or disease-
modifying antirheumatic drugs (methotrexate or sul-
fasalazine).
Isolation and culture of PBMCs
Peripheral blood mononuclear cells (PBMCs) from
healthy volunteers, RA patients, and SLE patients were iso-
lated from 20 ml heparinized peripheral blood by Ficoll-
Paque gradient centrifugation (Invitrogen) and then
washed twice with phosphate buffered saline (PBS). The
viability of PBMCs was >96% as determinded by trypan
blue staining, and the purity of human T and B lym-
phocytes isolated was >90% as tested with anti-CD3 mAb
and anti-CD19 mAb by flow cytometry. The isolatedBMC Musculoskeletal Disorders 2009, 10:141 http://www.biomedcentral.com/1471-2474/10/141
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PBMCs were divided into two groups: one group was used
for Western blotting and Immunocytochemistry; in the
other group, the PBMCs were resuspended at 1 × 106
PBMC/ml in RPMI-1640 medium supplemented with
10% bovine fetal serum, 2 mM glutamine, 100 U/ml pen-
icillin and 100 mg/ml streptomycin, then cultured with
PMA (Sigma) or TyrA9 (Calbiochem) in 24-well culture
dishes in 5% CO2 at 37°C to be used for further testing.
Control cultures without stimulants were included in each
experiment.
Western blotting
Freshly isolated PBMCs, 2 × 106, were lysed in 200 μl of
cold lysis buffer (1%Triton X-100, 0.5% NP-40, 150 mM
NaCl, 10 mM Tris [PH 7.4], 1 mM EDTA, 1 mM EGTA, 0.2
mM Na3VO4, 10 mM NaF, 0.2 mM PMSF, and protease
inhibitors mixture) and kept on ice on a shaking platform
for 30 minutes. After centrifugation at 12000 rpm for 10
minutes, supernatants were transferred to a fresh tube and
stored at -80°C. Protein concentrations were determined
with the BCA Protein Assay Kit (Santa Cruz Biotechnol-
ogy, CA, USA). From each sample preparation, 80 ug of
total proteins were mixed in Laemmli loading buffer,
boiled for 4 minutes, separated by 8% SDS-PAGE and
then transferred to PVDF blotting membranes (Gelman,
NY, USA). Membranes were blocked with the Tris buff-
ered saline-Tween/1% bovine serum albumin/1% nonfat
dry milk and incubated with rabbit polyclonal antibodies
specific for PYK2 (SC-9019), phospho-PYK2 (SC-11767-
R) and β-actin (SC-1616-R) (All from Santa Cruz Biotech-
nology, CA, USA) overnight at 4°C (diluted according to
the manufacturer's instructions). Polyclonal PYK2-spe-
cific antibody was used to detect the total protein level of
PYK2 while phospho-PYK2(p- PYK2) antibody which spe-
cifically recognizes PYK2 phosphorylation on tyrosine
402 to detect the activation of PYK2. β-actin was used as a
loading control to assure equal amounts of protein in all
lanes. After a final incubation with a 1:5000 dilution of
horseradish peroxidase-conjugated secondary antibodies
(Zhongshan Biotechnology, Beijing, China) for two hours
at room temperature, the membranes were developed
with an ECL detection system (Santa Cruz CA, USA). For
reprobing, the membranes were stripped in 0.2 M glycine
(PH 2.5)/0.05% Tween 20 at 80°C for 20 minutes.
Immunocytochemistry
Single immunoenzyme staining was performed using the
biotin-streptavidin peroxidase method with an LSAB-HRP
kit according to the manufacturer's instructions. Briefly,
the freshly isolated PBMCs suspensions were put on glass
slides and air-dried for at least 2 h, and either stained
immediately or stored at 80°C. After air drying, the cells
were fixed/permeablized with cytofix/cytoperm solution
for 20 min at 4°C, dried, and washed twice in PBS pH7.2
for 5 min. The cells were incubated with blocking solution
(included in kit) for 5 min in a humid atmosphere prior
to the addition of primary antibody specific for phospho-
PYK2 (SC-11767-R). Phospho-PYK2 antibody was added
at appropriate dilution (1:100) on slides and left for 30
min in a humid atmosphere at room temperature. The
cells were subsequently rinsed three times for 3 min in
PBS and then allowed to react for 10 min with bioti-
nylated antirabbit antibody (kit component). After a 3-
min rinse in PBS and incubation with streptavidin-horse-
radish peroxidase (LSAB kit) for 30 min, the cells were
washed three times in PBS (3 min each). They were then
developed in diaminobenzidine, and the reaction was
stopped by dipping the slides in distilled water. The cells
were counterstained with 1% hematoxylin and covered
with coverslips, and then examined under a light micro-
Table 1: Clinical features of patients with active SLE and patients with inactive SLE*
Characteristic Patients with active disease Patients with inactive disease
(n = 36) (n = 12)
No. of men/no. of women 5/31 2/10
Age, mean ± SD (range) years 35 ± 14 (11--69) 36 ± 12 (16--59)
Disease duration, mean ± SD (range) months 65 ± 101 (1--260) 118 ± 98 (5--216)
Disease activity
SLEDAI score (0--105), mean ± SD 16 ± 4 7 ± 4
Anti-dsDNA titer, mean ± SD IU/ml 597 ± 784 49 ± 56
CH50 level, mean ± SD units/ml 14 ± 11 26 ± 8
Clinical manifestation
WHO class IV nephritis 24 5
Other than WHO class IV nephritis 12 7
CNS disease 6 0
Treatment at time of study
None 10 0
≤10 mg/day prednisolone 28 9
Immunosuppressive agents 7 1
* Except where indicated otherwise, values are the number of patients.BMC Musculoskeletal Disorders 2009, 10:141 http://www.biomedcentral.com/1471-2474/10/141
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scope. Positive cells were counted under ×400 magnifica-
tion in 10 randomly chosen fields by two independent
observers in a blind fashion. The results from these two
observers were averaged to obtain the percentages of pos-
itive cells per sample.
Cell staining and flow cytometric analysis
The cultured PBMCs of each well in suspension were
stained with PE-CD40L (TRAP1, BD Biosciences) and PE-
CTLA4 (BNI3, BD Biosciences) for 15 min at 4°C in the
dark, PE-IgG1κ was used as a control. After staining, the
cells were washed with cold PBS and were immediately
analyzed using EPICS XL-4 flow cytometry along with sys-
tem software (Becton Dickinson, San Jose, CA). The PE
fluorescence intensity in PBMCs were measured using an
argon laser with an excitation wavelength of 488 nm and
emission wavelengths of 575 nm. The PBMCs were tightly
gated by volume and complexity on S forward (0°) and
side-light scattering (90°) mode. At least 1 × 104 cells were
analyzed for each determination.
Proliferation assays
For assaying PBMCs proliferation by PYK2 activation, iso-
lated human PBMCs (2 × 105 cells/well) were cultured for
24 h in 96-well flat-bottomed microtitre plates in RPMI
1640 containing 10% FCS, stimulated with PMA or TyrA9
for the indicated duration. The cultures were pulsed with
[3H]-thymidine (1.0 μCi/well) 18 h before harvesting the
cells, and [3H]-thymidine incorporation was measured in
a Microbeta Plus liquid scintillation counter (Wallac,
Gaithersburg, MD, USA). Cultures were run in triplicate,
and each experiment was repeated at least three times.
Statistical analysis
All data were expressed as mean ± standard deviation. A
one-way analysis of variance (ANOVA) test was used for
comparison of more than two groups. The differences
between the groups were assessed with the Post-Hoc Bon-
ferroni test. The analysis of correlations between clinical
variables and levels of p-PYK2 was based on Pearson rank
test. The level of significance was set to p < 0.05. The data-
set was analyzed using the SPSS V 13.0 statistical package.
Each experiment was repeated at least 3 times to assess
reproducibility.
Results
PYK2 is increased and activated in PBMCs from patients 
with SLE
To see the expression pattern and the activation of PYK2
in PBMCs from patients with SLE, we used Western blot-
ting to evaluate the total amount and phosphorylated
form of PYK2 in freshly isolated PBMCs from the SLE
patients. As controls, PBMCs from healthy donors and RA
patients were collected and processed simultaneously. As
show in Figure 1A (top blot), the intensity of PYK2 band
in PBMCs from SLE patients was higher than those from
either heathly controls or patients with RA. Quantitative
analysis shows PYK2 in PBMCs from SLE, but not RA
patients (0.96 ± 0.34 in RA), was significantly up-regu-
lated (1.13 ± 0.35 and 1.28 ± 0.30) in inactive and active
SLE patients, respectively, compared with that from
healthy donors (0.94 ± 0.41). Consistently, while PYK2
was weakly phosphorylated on the tyrosine 402 residue in
healthy donors and RA patients, a much thicker band cor-
responding to p-PYK2 was seen in lanes of the SLE
patients as shown in Figure 1A (middle blot). This has
also been further verified by quantitative analysis in
which the level of p-PYK2 was significantly higher in
PBMCs from SLE patients (0.97 ± 0.31 for inactive and
1.07 ± 0.33 for active), but not in PBMCs from RA patients
(0.81 ± 0.34), compared with normal PBMCs (0.77 ±
0.33) (Figure 1B). The ratio of p-PYK2/PYK2 was exam-
Enhanced expression and activation of PYK2 in SLE patients Figure 1
Enhanced expression and activation of PYK2 in SLE 
patients. (A) Representative blot of total PYK2 and p-PYK2 
in PBMCs lysates proteins obtained from healthy donors (n = 
24), patients with RA (n = 32), and patients with inactive (n = 
12) or active (n = 36) SLE. Total proteins obtained from 
PBMCs lysates were examined by Western blotting analysis 
for PYK2 and p-PYK2 as indicated in patients and methods. 
Lane 1 and 2, healthy donors;Lane 3 and 4, RA patients;Lane 
5 and 6, inactive SLE patients;Lane 7 and 8, active SLE 
patients. (B) The ratio between the optical density of specific 
bands and β-actin of the same sample was calculated and 
expressed graphically. The experiments for each sample 
were repeated at least three times and bars represent the 
mean and standard deviation of three separate experiments. 
Statistical comparison of all groups was made with healthy 
donors. The significance level was set at* = P < 0.05.
PYK2      116KD
P-PYK2   116KD
-actin    41KD
(B)
￿
￿
￿BMC Musculoskeletal Disorders 2009, 10:141 http://www.biomedcentral.com/1471-2474/10/141
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ined and no significant difference was found between SLE
patients (0.88 ± 0.19 for inactive SLE and 0.86 ± 0.20 for
active SLE), RA patients (0.85 ± 0.21) and healthy donors
(0.83 ± 0.18).
To identify in which sub-population of PBMCs the acti-
vated PYK2 is expressed, we immunostained phosphor-
ylated PYK2 in PBMCs from the samples mentioned
above with an antibody against p-PYK2. As observed in
Figure 2, p-PYK2 (2A and 2B) was not detectable in lym-
phocytes from healthy donors and RA patients, whereas in
lymphocytes from SLE patients, both the intensity and the
proportion of p-PYK2 immunostaining were increased
(2C). These data further confirmed results obtained by
Western blotting.
p-PYK2 is exclusively upregulated in SLE patients with 
class IV lupus nephritis and negatively correlated with the 
level of serum complement
We next assessed the correlation between the levels of p-
PYK2 and clinical manifestation of SLE. As shown in Fig-
ure 3A and 3B, the expression of p-PYK2 was markedly up-
regulated in PBMCs from SLE patients with class IV lupus
nephritis, whereas this up-regulation was not seen in
either healthy donors or SLE patients with CNS disease or
nephritis other than class IV. Next, we analyzed the corre-
lation between the ratio of p-PYK2/PYK2 and lupus
nephritis, and no correlation was found for class IV lupus
nephritis (data not shown). Furthermore, PYK2 activation
and serum complement level (CH50) showed a signifi-
cant negative correlation (Figure 3C). However, PYK2 acti-
vation did not show a correlation with the SLEDAI score
(data not show). These results suggest that up-regulation
of p-PYK2 in PBMCs is likely to be correlated with class IV
nephritis.
Enhanced PYK2 phosphorylation in PBMCs in response to 
lymphocyte activation stimulated by PMA
In vivo, lymphocytes often receive multiple stimuli and
become activated to carry out their biologic functions. To
understand the molecular events during lymphocyte acti-
vation and analyze the role played by PYK2, we tested the
effect of PMA on phosphorylation of PYK2. PBMCs
obtained from healthy donors, RA and SLE patients were
treated with PMA or medium in 24-well culture dishes in
5% CO2 at 37°C for 24 h, and the status of PYK2 Y402
phosphorylation was analyzed by western boltting. As
show in Figure 4A, the intensity of p-PYK2 band in PBMCs
stimulated by PMA was higher than those stimulated by
medium (Figure 4A). Quantitative analysis shows that p-
PYK2 in PBMCs stimulated by PMA, but not by medium,
was significantly up-regulated in healthy control (1.10 ±
0.32 VS 0.77 ± 0.29), RA (1.12 ± 0.35 VS 0.81 ± 0.30) and
SLE (1.47 ± 0.36 VS 1.08 ± 0.34) patients, respectively
(Figure 4B). These results indicate that when PBMCs were
Expression of p-PYK2 in PBMCs from SLE patients Figure 2
Expression of p-PYK2 in PBMCs from SLE patients. 
Detection of p-PYK2 protein in PBMCs from healthy donors 
(n = 24), patients with RA (n = 32), and patients with SLE (n 
= 48) was performed by immunocytochemistry technique 
using specific anti-p-PYK2 Abs. p-PYK2 was weakly positive 
in PBMCs from healthy donors (A) and RA patients (B). An 
increase in the positive staining for p-PYK2 was observed in 
PBMCs from SLE patients (C). Original magnification, × 400. 
Experiments were repeated at least three times with similar 
results.
   
A 
 
                       B  
 
                       C  BMC Musculoskeletal Disorders 2009, 10:141 http://www.biomedcentral.com/1471-2474/10/141
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(A) Activation of PYK2 in PBMCs from healthy donors (n = 24) and SLE patients with central nervous system (CNS) disease (n  = 6), WHO class IV nephritis (n = 29), or nephritis other than WHO class IV (n = 19) Figure 3
(A) Activation of PYK2 in PBMCs from healthy donors (n = 24) and SLE patients with central nervous system 
(CNS) disease (n = 6), WHO class IV nephritis (n = 29), or nephritis other than WHO class IV (n = 19). Total 
proteins obtained from PBMCs lysates were examined by Western blotting analysis for p-PYK2 as indicated in patients and 
methods. Lane 1, healthy donors;Lane 2, SLE patients with central nervous system; Lane 3, lupus nephritis other than WHO 
class IV;Lane 4, lupus nephritis IV. (B) The ratio between the optical density of specific bands and β-actin of the same sample 
was calculated and expressed graphically. The experiments for each sample were repeated at least three times and bars repre-
sent the mean and standard deviation of three separate experiments. Statistical comparison of all groups was made with 
healthy donors. The significance level was set at* = P < 0.05. (C) Correlation between PYK2 activation in PBMCs and serum 
levels of CH50 in SLE patients (n = 36).
(A)
p-PYK2 116KD
-actin  41KD
(B)
(C) BMC Musculoskeletal Disorders 2009, 10:141 http://www.biomedcentral.com/1471-2474/10/141
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stimulated by PMA, the total level of PYK2 Y402 phospho-
rylation is enhanced.
p-PYK2 in PBMCs from SLE patients induces the 
expression of CD40L and CTLA4
To further characterize the role of p-PYK2 in lymphocyte
activation, we assayed the cell surface costimulatory mol-
ecules expression by stimulating or inhibiting PYK2 phos-
phorylation, using PMA and PYK2 kinase inhibitor TyrA9,
respectively. As expected, using PMA to stimulate PBMCs
from active SLE resulted in a significant upregulation of
CD40L and CTLA4, whereas this upregulation is not
observed in PBMCs pretreated with chemical inhibitor of
PYK2 kinase activity (Figure 5C). In PBMCs from normal
individuals and RA patients, CD40L and CTLA4 expres-
sion were also significantly upregulated by stimulation
with PMA. This effect, however, cannot be suppressed by
administration of TyrA9 (Figure 5A, B). These results sug-
gest that p-PYK2 acts as an important mediator in PMA-
induced induction of CD40L and CTLA4 in PBMCs of
SLE.
p-PYK2 promotes the proliferation of SLE PBMCs
To explore whether upregulation of p-PYK2 may contrib-
ute to the pathogenesis of SLE, we cultured PBMCs from
patients with this condition as well as from those with RA
and healthy controls. Cultured cells were subjected to
groups in the presence or absence of TyrA9 before stimu-
lated with PMA and the subsequent cell proliferation
assay. We found in cultures without TyrA9, the prolifera-
tion of PBMCs from all sources were enhanced by PMA.
However, in the presence of TyrA9, only PBMCs from SLE
patients showed a repressed proliferation when stimu-
lated with PMA (Figure 6). These results indicate p-PYK2
transduces an activation signal for cell proliferation exclu-
sively in PBMCs of SLE.
Discussion
In this study, we found an upregulation of PYK2 in
PBMCs of SLE patients and an activation in SLE with class
IV lupus nephritis. We also found the activation is nega-
tively correlated with the level of serum complement. By
isolating and culturing the PBMCs, we verified p-PYK2 a
mediator specific to SLE to induce costimulatory mole-
cules CD40L and CTLA4, and to promote the cell prolifer-
ation. This study represents the first demonstration that
PYK2 expression and activation appear exclusive in SLE
PBMCs and crucial for the pathogenesis of SLE.
Lymphocyte activation is a fundamental component
implicated in the production of autoantibodies in SLE
patients. Understanding the precise molecular mecha-
nism of SLE lymphocyte activation will be important to
develop novel therapeutic strategies targeting reduction
autoantibodies and to increase the sensitivity of current
treatment modalities. PYK2, a nonreceptor protein tyro-
sine kinase which plays pivotal roles in the regulation of
lymphocyte activation[33], has drawn our attention in
considering the lymphocyte activation in SLE.
Our studies showed no detection of p-PYK2 in PBMCs of
RA and healthy controls. PYK2 in SLE PBMCs is not only
increased but also phosphorylated at tyrosine 402 resides.
These findings suggest that upregulation and activation of
PYK2 may be implicated in the pathogenesis of SLE.
PYK2 has been reported overexpressed in glomeruli but
not in other tissues of human and rat crescentic glomeru-
lonephritis, and its overexpression is closely associated
with the onset of glomerulonephritis[40]. In our study,
we showed a marked upregulation of p-PYK2 in PBMCs
from SLE patients with class IV lupus nephritis, but not
healthy donors or SLE patients with CNS disease or
nephritis other than class IV. Further, we found clear neg-
ative correlation between the levels of p-PYK2 and serum
CH50. It suggests that signaling pathway involving PYK2
Enhanced PYK2 phosphorylation in PBMCs in response to  lymphocyte activation stimulated by PMA Figure 4
Enhanced PYK2 phosphorylation in PBMCs in 
response to lymphocyte activation stimulated by 
PMA. (A) PBMCs obtained from healthy donors (n = 24), 
RA patients (n = 32) and SLE patients (n = 48) were incu-
bated in 24-well culture dishes in 5% CO2 at 37°C for 24 h 
for with no stimulation (medium), or stimulation with PMA 
(1 ng/ml). Lysates prepared from 2 × 106 cells were analyzed 
by western blotting for the expression of p-PYK2 as indi-
cated in patients and methods. (B) p-PYK2 expressed relative 
to the value obtained with PMA stimulation. Bars represent 
the mean and standard deviation of three separate experi-
ments. Statistical analysis: * = p < 0.05.
(A)
PMA(1ng/ml) 
p-PYK2 116KD
-actin  41KD
(B)BMC Musculoskeletal Disorders 2009, 10:141 http://www.biomedcentral.com/1471-2474/10/141
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Up-regulation of CD40L and CTLA-4 by PYK2 activation in PBMCs from patients with active SLE (C), but not those from nor- mal individuals and RA patients (A and B) Figure 5
Up-regulation of CD40L and CTLA-4 by PYK2 activation in PBMCs from patients with active SLE (C), but not 
those from normal individuals and RA patients (A and B). PBMCs were incubated for 24 h with medium, PMA (1 ng/
ml) or pretreated with the PYK2 inhibitor TyrA9 (5 μM) for 1 h before the addition of PMA, and then analyzed for the expres-
sion of CD40L and CTLA4 by flow cytometric analysis. All experiments were repeated at least three times with similar results. 
Statistical analysis: * = p < 0.05.
(A) 
(B) 
(C) 
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are likely to play a role in the development and progres-
sion of nephritis.
FAK, the prototype of PYK2, mediates signaling in active
SLE enhancing autoreactive T cell activation by prolifera-
tion and by upregulating the expression of costimulatory
molecule CD40L[16]. PYK2 also provides important sig-
nals to T and B lymphocyte activation[33,34]. Its expres-
sion and activation, however, are not seen in PBMCs from
RA patients. We explored whether the similar scenario will
happen in SLE. Given that costimulatory molecules are
known to be a prerequisite for lymphocyte activation, we
answered this question by checking the expression of cos-
timulatory molecules and subsequent proliferation in SLE
PBMCs. In contrast to what has been observed in RA,
PYK2 was shown exclusively in SLE a mediator of activa-
tion signaling of proliferation. Therefore, PYK2-mediated
activation of lymphocytes is not only functionally
enhanced in SLE but also a process specific to SLE. Taking
into account the limitations that chemical inhibitor of
Pyk2 kinase activity is almost never perfect in its specifi-
city, in subsequent experiments, we are going to use RNA-
mediated interference, Pyk2-deficient PBMCs and domi-
nant negative Pyk2 mutants to confirm the exact function
of Pyk2 in regulating SLE PBMCs proliferation.
Abnormal T and B lymphocytes activation and lym-
phocytes death underlie the pathology of SLE[41]. Poten-
tially autoreactive T and B lymphocytes are removed by
apoptosis during development and after completion of an
immune response. Paradoxically, lupus T cells exhibit
both enhanced spontaneous apoptosis and defective acti-
vation-induced cell death [42]. Increased spontaneous
apoptosis has been linked to chronic lymphopenia in
patients with SLE[42]. By contrast, defective activation-
induced cell death (AICD) may be responsible for persist-
ence of autoreactive T and B lymphocytes, leading to
expansion of antigen-spectific T cell clones[42]. Indeed, in
prototypical murine SLE models (i.e., lpr/lpr and gld/gld
mice), the animals are defective in Fas and FasL, respec-
tively, which are critical elements in T cell apoptosis. Our
result demonstrate that in addition to increased phospho-
rylation of PYK2 in SLE PBMCs, phosphorylated PYK2 sig-
naling could also enhances the autoreactive lymphocyte
activation and proliferation (Fig.5 and Fig.6). However,
the mechanism that phosphorylated PYK2 induce lym-
phocyte proliferation is not clear. It would be interesting
to investigate whether phosphorylated PYK2 could pro-
mote lymphocyte activation and proliferation via inhibi-
tion of apoptosis or via enhanced hyperreactivity of
lymphocyte.
Our results, together with those of earlier studies, demon-
strate that the PBMCs from SLE patients exhibit both
increased activation and enhanced activity of PYK2. We
strongly propose PYK2 a major contributor to the com-
plex autoimmune pathogenesis of SLE.
Conclusion
In the present study, We found a significant increase of
both the total PYK2 protein and its activated/phosphor-
ylated form in PBMCs from patients with SLE, particularly
those with the complication of nephritis (WHO IV). There
is a clear inversly correlation between the activation of
PYK2 and the level of serum complements. In active SLE
patients, activation of PYK2 in PBMCs is accompanying
the increased cell proliferation and the induced expres-
sion of costimulatory molecules CD40L and CTLA4.
These results indicate that phosphorylated PYK2 may
induce the expression of CD40L and CTLA4, and subse-
quently the cell proliferation. PYK2 signaling enhances
the autoreactive lymphocyte activation and plays an
important role in the pathogenesis of SLE.
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